

ATHEROGENICS INC  
Form 8-K  
June 16, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): June 16, 2009**

**ATHEROGENICS, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Georgia**

(State or other jurisdiction  
of incorporation)

**0-31261**

(Commission  
File Number)

**58-2108232**

(I.R.S. Employer  
Identification Number)

**8995 Westside Parkway**

**Alpharetta, GA 30009**

(Address of principal executive offices)

Registrant's telephone number, including area code **(678) 336-2500**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events**

AtheroGenics, Inc. (the Company ) is required to file monthly operating reports in the United States Bankruptcy Court for the Northern District of Georgia (the Bankruptcy Court ). On June 16, 2009, the Company filed its monthly operating report for the month ended May 31, 2009 with the Bankruptcy Court. Selected financial information for the month of April included in the monthly operating report (the Selected Financial Information ) is attached hereto as Exhibit 99.1.

The information contained in the Selected Financial Information is preliminary and subject to revision, and the Company cautions readers not to place undue reliance upon this information. The Selected Financial Information is unaudited, in a format prescribed by applicable bankruptcy laws, and has not been prepared in conformity with generally accepted accounting principles. The information in the Selected Financial Information might not be indicative of the Company s financial condition or operating results for the period that would be reflected in the Company s financial statements or in a periodic report filed pursuant to the Securities Exchange Act of 1934, as amended. The information set forth in the Selected Financial Information should not be viewed as indicative of future results and should not be used for investment purposes.

**Item 9.01. Financial Statements and Exhibits.**

The following exhibit is furnished as part of this current report on Form 8-K.

Exhibit No.	Description
99.1	Selected Financial Information

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**ATHEROGENICS, INC.**

Date: June 16, 2009

By: /s/ CHARLES A. DEIGNAN  
Charles A. Deignan  
President, Chief Financial Officer  
and Secretary

---

**EXHIBIT INDEX**

Exhibit No.	Description
99.1	Selected Financial Information